1Yamada A, Oguchi K, Fukushima M, et al . Evaluation of 2-deoxy- 2-[18F] fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor inva- sion, and glucose transporter-I expression [ J ]. Ann Nucl Med, 2006,20(9) :597-604.
2Shows TB, Eddy RL, Byers MG, et al. Polymorphic human glucose transporter gene(GLUT) is on chromosome 1 p31.3-p35 [ J]. Diabe- tes, 1987,36 (4) : 546 -549.
3Medina RA, Meneses AM, Vera JC, et al. Differential regulation of glucouse transporter expression by estrogen and progesterone in Ish- ikawa endometrial cancer cells [ J ]. J Endocrinol, 2004,182 ( 3 ) : 467-478.
4Lurid EL, Hog A, Olsen MW, et al. Differential regulation of VEGF, HIFlalpha and angiopoietin-1 ,-2 and -4 by hypoxia and ionizing radiation in human glioblastoma [ J ]. Int J Cancer,2004, 108(6) :833-838.
5Joost HG, Thorens B. The extended GLUT-family of sugar/polyol transport facilitators : nomenclature, sequence characteristics, and potential function of its novel members (review) [ J]. Mol Membr Bio1,2001,18(4) 247-256.
6Cantuaria G, Magalhaer A, Penalver M, et al. Expression of GLUT- 1 glucose transporter in borderline and malignant epithelial tumorsof the ovary[J]. Gynecol Onco1,2000,79( 1 ) :33-37.
8Cantuaria G, Fagotti A, Ferrandina G, et al. GLUT-I expression it ovarian carcinoma:association with survival and response to chemo. therapy [ J ]. Cancer,2001,92 (5) : 1144-1150.
7Morin PJ. Beta-catenin signaling and cancer[J]. Bioessays, 1999, 21(12):1021-1030.
8Pirinen RT, Hirvikoski P, Johansson RT, et al. Reduced expression of alpha-catenin, beta-eatenin, and gammacatenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung eaneer [J]. J Clin Pathol, 2001, 54(5): 391-395.
9Chen Z, Lu W, Garcia-Prieto C, et al. The Warburg effect and its cancer therapeutic implications [J]. J Bioenerg Biomembr, 2007, 39(3): 267-274.
10Ravazoula P, Batistatou A, Aletra C, et al. Immunohistochemical expression of glucose transporter Glutl and cyclin D1 in breast carcinomas with negative lymph nodes [J]. Eur J Gynaecol Oncol, 2003, 24(6): 544-546.
